All Stories

  1. Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial
  2. Managing congestive heart failure: It is mostly about water, not salt!
  3. Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure
  4. Association of non-cardiac comorbidities and sex with long-term Re-hospitalization for heart failure
  5. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
  6. Integrative assessment of congestion in heart failure using ultrasound imaging
  7. REVOLUTION in Heart Failure Care and SELECT Highlights From the European Society of Cardiology-Heart Failure Association Heart Failure & World Congress on Acute Heart Failure 2024
  8. Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
  9. Disease progression in chronic heart failure is linear: Insights from multistate modelling
  10. Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?
  11. Loop diuretic therapy with or without heart failure: impact on prognosis
  12. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
  13. The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction
  14. Prognostic implication of lung ultrasound in heart failure: a pooled analysis of international cohorts
  15. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
  16. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
  17. Low Serum Ferritin Might Predict Incident Heart Failure
  18. Multi-modality assessment of congestion in acute heart failure: Associations with left ventricular ejection fraction and prognosis
  19. ACHIEVE conference proceedings: implementing action plans to reduce and control hypertension burden in Africa
  20. Priorities to reduce the burden of hypertension in Africa through ACHIEVE
  21. Estimation of Right Atrial Pressure by Ultrasound-Assessed Jugular Vein Distensibility in Patients With Heart Failure
  22. Reply to ‘Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?’
  23. Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis
  24. Atrial myopathy and heart failure with preserved ejection fraction: When a label does more harm than good?
  25. Medicines optimization prior to discharge in patients admitted to hospital with heart failure
  26. How to diagnose and treat venous congestion in heart failure
  27. Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS‐986231)
  28. Multiple Cardiac Biomarkers to Improve Prediction of Cardiovascular Events: Findings from the Generation Scotland Scottish Family Health Study
  29. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial
  30. Hospital admissions in the last year of life of patients with heart failure
  31. Lung ultrasound in acute and chronic heart failure: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI)
  32. Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure
  33. Coronary revascularization for heart failure with coronary artery disease: A systematic review and meta‐analysis of randomized trials
  34. Defining Heart Failure Based on Imaging the Heart and Beyond
  35. Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease
  36. Correction to: Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: A Practical Guide
  37. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
  38. A machine learning‐derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial
  39. Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide
  40. Urinary Proteomic Signature of Mineralocorticoid Receptor Antagonism by Spironolactone: Evidence from the Randomized-Controlled HOMAGE and PRIORITY Trials
  41. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials
  42. Inferior vena cava diameter is associated with prognosis in patients with chronic heart failure independent of tricuspid regurgitation velocity
  43. Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis
  44. Redefining both iron deficiency and anaemia in cardiovascular disease
  45. Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)
  46. Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis
  47. Editorial: Edema in heart failure with reduced ejection fraction
  48. Genetic architecture of the HLA/MHC locus in cardiometabolic disease, severe mental illness, and related traits.
  49. The incremental value of multi-organ assessment of congestion using ultrasound in outpatients with heart failure
  50. Identification and quantification of congestion in heart failure: a work in progress
  51. Correction: Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications
  52. Which frailty tool best predicts morbidity and mortality in ambulatory patients with heart failure? A prospective study
  53. Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications
  54. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
  55. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
  56. Ketone Bodies in Acute Heart Failure: Fuel for Thought
  57. Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial
  58. Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials
  59. Chronic kidney disease (CKD) and CKD ‐ism in heart failure – what a mess!
  60. Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges
  61. Reply to ‘Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease’
  62. Albuminuria as a marker of systemic congestion in patients with heart failure
  63. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial
  64. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
  65. Rationale and design of a randomised trial of intravenous iron in patients with heart failure
  66. Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
  67. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial
  68. Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure
  69. Are non-invasive estimations of plasma volume an accurate measure of congestion in patients with chronic heart failure?
  70. Remote laser-speckle sensing of heart sounds for health assessment and biometric identification
  71. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
  72. Heart failure: age is no excuse for complacency
  73. Chronic Obstructive Pulmonary Disease and Heart Failure
  74. Predicting mortality after hospitalisation for COPD using electronic health records
  75. Practical outpatient management of worsening chronic heart failure
  76. Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank
  77. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
  78. Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice
  79. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial
  80. Criteria for Iron Deficiency in Patients With Heart Failure
  81. Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
  82. Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives
  83. Prognostic Value and Therapeutic Utility of Lung Ultrasound in Acute and Chronic Heart Failure
  84. Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF
  85. Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
  86. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
  87. No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
  88. The effect of digoxin on renal function in patients with heart failure
  89. The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure
  90. Congestion in Patients with Advanced Heart Failure
  91. To master heart failure, first master congestion
  92. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design
  93. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
  94. A novel treatment for heart failure targets myocardial fibrosis
  95. Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening
  96. Use of Social Media by Cardiovascular Health Care Professionals
  97. Reply to the letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’
  98. Remote history of VTE is associated with severe COVID‐19 in middle and older age: UK Biobank cohort study
  99. A comparison of non‐invasive methods of measuring body composition in patients with heart failure: a report from SICA‐HF
  100. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure
  101. Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA‐REG OUTCOME trial
  102. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
  103. The struggle towards a Universal Definition of Heart Failure—how to proceed?
  104. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
  105. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials
  106. Prognostic value of the chest X-ray in patients hospitalised for heart failure
  107. The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
  108. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies
  109. The Effect of Digoxin on Renal Function in Patients with Heart Failure
  110. The association between blood groups and COVID‐19 infection: a study from the UK Biobank
  111. Effect of frailty on treatment, hospitalisation and death in patients with chronic heart failure
  112. The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure
  113. Ultrasound imaging of congestion in heart failure: examinations beyond the heart
  114. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
  115. Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies
  116. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
  117. Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition
  118. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
  119. Driving Habits and Reaction Times on a Driving Simulation in Older Drivers With Chronic Heart Failure
  120. Caring for people with heart failure and many other medical problems through and beyond the COVID ‐19 pandemic: the advantages of universal access to home telemonitoring
  121. At the heart of COVID-19
  122. Association Between Walking Pace and Stroke Incidence
  123. Ultrasound indices of congestion in patients with acute heart failure according to body mass index
  124. Agreement and Classification Performance of Malnutrition Tools in Patients with Chronic Heart Failure
  125. Eplerenone prevents an increase in serum carboxy‐terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure
  126. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing ...
  127. OUP accepted manuscript
  128. Chronic Obstructive Pulmonary Disease and Heart Failure
  129. Association of Fitness and Grip Strength With Heart Failure
  130. Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure
  131. Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients with Heart Failure
  132. High sensitivity C-Reactive Protein in Chronic Heart Failure: Patient Characteristics, Phenotypes and Mode of Death
  133. New perspectives and future directions in the treatment of heart failure
  134. Prevention or Procrastination for Heart Failure?
  135. Clinical and prognostic association of total atrial conduction time in patients with heart failure
  136. Identification of Frailty in Chronic Heart Failure
  137. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure
  138. The prognostic role of different renal function phenotypes in patients with acute heart failure
  139. Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure
  140. Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality
  141. Warm water immersion in patients with chronic heart failure: a pilot study
  142. Malnutrition, congestion and mortality in ambulatory patients with heart failure
  143. Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure
  144. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life
  145. Losing Track by Tracking Speckles
  146. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose–response meta-analysis
  147. Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance
  148. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure
  149. Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction
  150. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study
  151. Clinical and prognostic relationships of pulmonary artery to aorta diameter ratio in patients with heart failure: a cardiac magnetic resonance imaging study
  152. Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure
  153. Time to Take the Failure Out of Heart Failure
  154. Interatrial shunt devices for heart failure with normal ejection fraction: a technology update
  155. Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?
  156. This patient is not breathing properly: is this COPD, heart failure, or neither?
  157. Takotsubo syndrome in the paediatric population
  158. Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: preliminary experience. A report from the SICA-HF study
  159. The effects of short-term omission of daily medication on the pathophysiology of heart failure
  160. New pharmacological approaches in heart failure therapy: developments and possibilities
  161. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
  162. Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction
  163. Is Swimming Safe in Heart Failure? A Systematic Review
  164. Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocar...
  165. Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure
  166. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life
  167. Tachycardia-induced cardiomyopathy in pregnancy
  168. PARADIGM-HF: does dose matter?
  169. Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure
  170. Taxonomy of segmental myocardial systolic dysfunction
  171. Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements
  172. New ways to visualize and combat congestion in heart failure
  173. Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Survey-1
  174. The effect of increasing inspired oxygen on exercise performance in patients with chronic heart failure
  175. Exploring quality of life in patients with and without heart failure
  176. Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure
  177. The Prevalence of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction and its Association with Elevated Pulmonary Pressure, Reduced Exercise Capacity and Quality of Life
  178. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure
  179. The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis
  180. The relationship of QRS morphology with cardiac structure and function in patients with heart failure
  181. If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?
  182. Update on management of heart failure with preserved ejection fraction
  183. Prescribing Patterns to Optimize Heart Rate
  184. Is the Epidemic of Heart Disease Really Over or Just Evolving?
  185. Patent Ductus Arteriosus in Older Adults: Incidental Finding or Relevant Pathology?
  186. The Prevalence of Extra-cranial Carotid Artery Disease in Chronic Heart Failure
  187. Fluid Management In Patients With Chronic Heart Failure
  188. Heart failure with preserved ejection fraction
  189. Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM‐HF, CONFIRM‐HF, SIGNIFY, atrial fibrillation, beta‐blockers and heart failure, and vagal stimulation in heart failure
  190. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value
  191. Lipid-Modifying Treatments for Heart Failure
  192. Does Speckle Tracking Really Improve Diagnosis and Risk Stratification in Patients With HF With Normal EF?
  193. Diagnostic Accuracy of Left Ventricular Systolic Dysfunction in Routine Clinical Practice-Classifying the Unclassified
  194. Muscle Wasting in Patients with Heart Failure with Preserved Ejection Fraction and Its Impact on Muscle Strength and Functional Capacity during Exercise
  195. Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?
  196. Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction
  197. Telemonitoring in heart failure: Big Brother watching over you
  198. THE OBESITY PARADOX IN TYPE II DIABETES MELLITUS: IMPACT OF BODY MASS INDEX ON PROGNOSIS
  199. Multiple Cardiac Clots in an Individual with Essential Thrombocythemia and Heart Failure
  200. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature
  201. Revisiting a classical clinical sign: Jugular venous ultrasound
  202. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?
  203. Case Selection for Cardiac Resynchronization in Atrial Fibrillation
  204. Old and newer biomarkers in heart failure
  205. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty
  206. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function
  207. Why Does CRT Reduce the Risk of Arrhythmias?
  208. Fish Oil vs Olive Oil for Postoperative Atrial Fibrillation
  209. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease
  210. Defining Diastolic Heart Failure and Identifying Effective Therapies
  211. Medical Management of Stable Coronary Atherosclerosis
  212. IVC Diameter in Patients With Chronic Heart Failure
  213. An atrial mass
  214. A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure
  215. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis
  216. Subclinical Anthracycline Cardiotoxicity in Patients With Acute Promyelocytic Leukemia in Long‐Term Remission After the AIDA Protocol
  217. Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT
  218. Cor triatriatum: Transoesophageal three-dimensional reconstruction shows exact membrane morphology